UCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager deal

Under the agreement, UCB gains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, along with access to Antengene’s associated manufacturing technology for the drug. Antengene will pocket $80 million in upfront and near-term milestones, with the chance to earn up to about $1.1 billion in additional development and commercial milestones, plus tiered royalties on sales. 

A “masked” T-cell engager built for autoimmunity

ATG-201 belongs to a class best known for oncology: bispecific antibodies that physically link T cells (via CD3) to a target cell (here, CD19+ B cells) to trigger killing. In blood cancers, the archetype is blinatumomab, a CD19/CD3 T-cell engager that proved the concept but also highlighted the risk of cytokine release syndrome (CRS) and the need for careful dosing and monitoring. 

Antengene’s pitch is that its AnTenGager platform is designed to make this modality more tolerable in non-oncology settings. The company describes a format where the CD3-binding arm is sterically “masked” unless the drug is bound to its target antigen, aiming to keep T cells quieter until they are in the right place, thereby reducing CRS risk while maintaining potency. 

Preclinical work presented by Antengene suggests ATG-201 can drive CD19-dependent T-cell activation with a low CRS signal, and showed activity in models used to study autoimmune disease mechanisms such as EAE (often used in multiple sclerosis research) and lupus-prone mice. 

How development will run

Antengene will take ATG-201 into the clinic first: it plans to submit clinical trial applications in China and Australia in Q1 2026, run first-in-human Phase 1 studies in those jurisdictions, and then hand over further clinical and other development to UCB. 

Alistair Henry, Chief Scientific Officer at UCB framed the deal as a way to “lead in immunology” while expanding into “transformational new capabilities” in bispecific T-cell engagers, part of a broader strategy to combine its antibody know-how with newer biologics platforms. 

T-cell engagers are moving beyond cancer

For years, autoimmune drug development has leaned heavily on B-cell depletion using antibodies against CD20 (e.g., rituximab-class drugs), which can be effective but don’t always fully eliminate disease-driving B-cell populations, and can leave patients vulnerable to infection with long-term immunosuppression. Reviews of the field have highlighted a shift toward more precise, deeper depletion strategies, including modalities that recruit the patient’s own immune cells (T cells) to remove pathogenic B cells. 

That’s where TCEs enter the conversation. T-cell engagers are a potentially powerful way to disrupt B- and T-cell collaboration in autoimmune diseases, drawing parallels with both anti-CD19 CAR-T results and oncology bispecifics. 

So far, bispecific licensing has been oncology-heavy, but autoimmune is increasingly attracting deal activity, with a notable share of assets coming out of Asian (including Chinese) biotech companies. A case in point came yesterday: RTW Investments-backed Prolium Bioscience launched with $50 million and said it has dosed first patients with PRO-203, a CD20xCD3 T-cell engager aimed at severe autoimmune diseases such as systemic sclerosis and lupus, and an asset Prolium in-licensed from China’s KeyMed Biosciences and InnoCare Pharma for global non-oncology rights (and ex-Asia oncology rights).

A fast-forming “deep B-cell reset” race

UCB’s move comes as other companies push T-cell engager approaches aimed at B-cell depletion in autoimmune disease, often with the same safety focus (reducing CRS) and with targets such as CD19 or BCMA. For example, in June last year, Cullinan Therapeutics licensed velinotamig, a BCMAxCD3 bispecific T-cell engager, from China’s Genrix Bio for development in autoimmune diseases. Under the agreement, Cullinan agreed to pay $20 million upfront for global rights outside Greater China, with Genrix eligible for up to $292 million in development and regulatory milestones, up to $400 million in sales-based milestones, plus tiered royalties on ex-Greater China net sales.

What’s driving the surge is the promise of a deeper “immune reset” than conventional B-cell–targeting antibodies have delivered, while avoiding the manufacturing complexity and hospital logistics of autologous CAR-T. In theory, a well-engineered T-cell engager could offer CAR-T-like depth of B-cell depletion in an off-the-shelf biologic: scalable manufacturing, repeatable dosing, and easier global rollout. The trade-off is that developers must prove they can control the modality’s biggest liability, cytokine release syndrome.

The first real industry signal will come quickly. If Phase 1 shows that the “masked” TCE concept can deliver meaningful B-cell depletion with manageable cytokine effects, it would strengthen the case that T-cell redirection therapies can be engineered for chronic immunology, not just cancer.

For UCB, the deal is also a statement of intent: immunology is becoming a proving ground for next-generation biologics platforms, and big players are willing to pay early to secure assets that could redefine what “targeted” immune modulation looks like in the next decade.